Prospective open- label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies.

MLA

Doneddu, Pietro Emiliano, et al. “Prospective Open- Label Trial with Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not Responding to Conventional Immune Therapies.” Journal of Neurology, Neurosurgery & Psychiatry, vol. 95, no. 9, Sept. 2024, pp. 838–44. EBSCOhost, https://doi.org/10.1136/jnnp-2023-332844.

APA

Doneddu, P. E., Cocito, D., Fazio, R., Benedetti, L., Peci, E., Liberatore, G., Falzone, Y. M., Germano, F., Gallia, F., Giannotta, C., Lleixà, C., Bianchi, E., & Nobile-Orazio, E. (2024). Prospective open- label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies. Journal of Neurology, Neurosurgery & Psychiatry, 95(9), 838–844. https://doi.org/10.1136/jnnp-2023-332844

Chicago

Doneddu, Pietro Emiliano, Dario Cocito, Raffaella Fazio, Luana Benedetti, Erdita Peci, Giuseppe Liberatore, Yuri Matteo Falzone, et al. 2024. “Prospective Open- Label Trial with Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not Responding to Conventional Immune Therapies.” Journal of Neurology, Neurosurgery & Psychiatry 95 (9): 838–44. doi:10.1136/jnnp-2023-332844.